Showing results (171-180 of 205) with videos related to
Sort By:
Pageof 21
Blood|December 14, 2011
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)Hagop M Kantarjian, Neil P Shah, Jorge E Cortes, et al.Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.The Lancet. Oncology|June 4, 2018
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJorge Cortes, Alexander E Perl, Hartmut Döhner, et al.Archiv Der Pharmazie|May 10, 2025
Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AMLNada Alaa El-Deen, RosaAnna DeFilippis, Amal Kamal Abdel-Aziz, et al.Cancer Discovery|May 16, 2019
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid LeukemiaChristine M McMahon, Timothy Ferng, Jonathan Canaani, et al.Nature Genetics|February 14, 2006
Germline KRAS mutations cause Noonan syndromeSuzanne Schubbert, Martin Zenker, Sara L Rowe, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Chronic Myelogenous Leukemia, Version 1.2014Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Chronic myelogenous leukemia, version 1.2015Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.BMC Cancer|April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemiaEhab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Testing of new agents in childhood cancer preclinical models: meeting summaryPeter J Houghton, Peter C Adamson, Susan Blaney, et al.Pageof 21